>VRTX SGP – The way it looks to me is that vertex is going to end up with a svr in the 60's in phase 3 for 24 week telaprevir based treatment, and sgp may also end up with a svr in the 60's in phase 3 with 48 WEEKS of treatment.<
Why do you keep talking about the raw SVR rate in these trials rather than the delta SVR between the active arm and the control arm? The delta SVR is of far greater consequence because it’s the only way to adjust for the characteristics of the treated population.
Did you read #msg-31208458? It discusses the proportion of patients in the Boceprevir trial who are African-American (16%) and the proportion who had cirrhosis on trial entry (7%). These are consequential figures, IMO, and yet you have not uttered a peep about them!
I suspect that if the shoe were on the other foot and VRTX were the one who had treated the more difficult patient population, you would be among the first to tell us about it.
Market Data 
Markets 
AI
